Kite Pharma, a Gilead Company, Identifies Genetic Markers for Predicting CAR-T Toxicity and Efficacy in Yescarta Clinical Trial
Breakthrough in CAR-T Safety Through Genomic Analysis
Gilead Sciences' subsidiary, Kite Pharma, has re-analyzed clinical data from Yescarta (axicabtagene ciloleucel), a CD19-targeted CAR-T cell therapy, and found that individual patient's genetic factors are key indicators in determining the treatment's side effects and efficacy. The Massachusetts General Hospital (MGH) research team analyzed the germline genetics of patients who participated in the ZUMA-1 and ZUMA-7, the major clinical trials of Yescarta, and identified specific gene mutations associated with the risk of toxicity. This research, published in the prestigious journal 'Science Immunology,' is garnering attention from both the academic and industrial communities.
Identification of STXBP2 Mutation and Opportunity to Overcome Severe Adverse Effects
The research team analyzed genes related to hemophagocytic lymphohistiocytosis (HLH), a rare and severe hyperinflammatory disease in children, and confirmed that patients with loss-of-function mutations in the STXBP2 (syntaxin binding protein 2) gene invariably experienced severe cellular toxicity after Yescarta administration. This is expected to be a crucial clue in elucidating the mechanism of cytokine release syndrome (CRS), the most life-threatening side effect of CAR-T therapy. In contrast, screening analysis of the entire genome revealed ADAMTSL3, a protective gene mutation that significantly reduces the risk of toxicity, paving the way for safer patient selection.
Improving Next-Generation Process Efficiency Through PTPN22 Inhibition
Notably, this study goes beyond predicting adverse effects and reveals the genetic mechanism of PTPN22, a T-cell activation-regulating gene that can maximize therapeutic efficacy. PTPN22 is a negative regulator that inhibits T-cell proliferation, and the study demonstrated through cross-validation of ZUMA clinical trial data that a specific mutation in this gene promotes the massive proliferation of CAR-T cells infused into the patient. Accordingly, if PTPN22 is intentionally inhibited or knocked out using gene editing technology (such as CRISPR) in the manufacturing process of cell therapies in the future, it is expected that the in vivo proliferative capacity of cell therapies can be maximized and the administration dose can be reduced, significantly improving commercial manufacturing efficiency.
Market Share Defense Strategy for Blockbuster Yescarta
Currently, the global CAR-T market is facing intensifying competition as Novartis' Kymriah and Bristol Myers Squibb's Breyanzi, among other strong competitors, threaten Yescarta's market position. Yescarta recorded $1.57 billion in sales in 2024, but with the offensive from competitors' pipelines and concerns about adverse effects, quarterly sales have been declining in 2025, making this discovery of genetic safety markers a potential breakthrough. Ultimately, by introducing a precision medicine design based on patient genetic information, clinical success rates can be improved, and regulatory hurdles can be lowered, leading to strategic commercialization in the near future.
Yescarta, approved by the FDA on October 18, 2017, has established itself as a blockbuster with $1.57 billion in annual sales in 2024, but its growth has slowed due to the penetration of follow-up competitors such as Novartis' Kymriah and BMS' Breyanzi. This study presents clinical evidence that can proactively block the occurrence of severe cytokine release syndrome (CRS), a critical limitation of CAR-T therapy, by pre-screening for STXBP2 mutations, which are genetic markers in the patient's germline. In the short term, it will serve as a catalyst for defending market share by maximizing treatment stability through patient-specific precision screening and alleviating concerns about market attrition. In the medium to long term, it is expected to provide a key competitive advantage in expanding the platform to the field of solid tumors by introducing a PTPN22 knockout process to significantly improve cell culture scalability and reduce manufacturing costs. This genomic biomarker study is analyzed as a key indicator that will not only improve Kite Pharma's process efficiency but also lead to improved regulatory approval success rates and reduced production costs for next-generation CAR-T pipelines.